Antibodies in serum and parotid saliva against cell wall preparations from four serotypes of S mutans were examined in 110 subjects aged 18 to 25 years. In subjects with no detectable carious lesions, significant negative correlations were found between the DMF index and serum IgG and IgM antibodies, especially in S mutans of serotype c, whereas positive correlations were found between the DMF index and salivary IgA antibodies. In subjects with active caries, positive correlations were found between serum IgG antibodies and S mutans (serotypes c and a) and the DMF index. Sequential antibody analysis during a period of up to 32 months showed that development of carious lesions was associated with a rise in serum antibody titer to S mutans, but no change was detectable in salivary antibodies. Treatment of caries led to a decrease in serum IgG and IgM antibodies to S mutans cell wall, but in parotid saliva an increase in antibody titer to a culture extract of S mutans was found. The results support the concept of dental caries as an infective disease and suggest that serum antibodies may contribute to caries immunity in man.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/002203457605500306011 | DOI Listing |
J Appl Lab Med
January 2025
ARUP Laboratories, Salt Lake City, UT, United States.
Background: Detection of serum-specific immunoglobulin G (sIgG) to Aspergillus fumigatus traditionally relied on precipitin assays, which lack standardization and have poor analytical sensitivity. Automated quantitative immunoassays are now more widely used alternatives. A challenge, however, is determining reference interval (RI) cutoffs indicative of disease presence.
View Article and Find Full Text PDFJ Clin Microbiol
January 2025
Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
Unlabelled: The World Health Organization (WHO) 2030 roadmap for schistosomiasis calls for development of highly sensitive and specific diagnostic tools to continue and sustain progress towards elimination. Serological assays are excellent for sensitive detection of primary schistosome infections and for schistosomiasis surveillance in near- and post-elimination settings. To develop accurate assay formats, it is necessary to identify defined antibody targets with low cross-reactivity and potential for standardized production.
View Article and Find Full Text PDFBackground: Imlifidase is an IgG-cleaving endopeptidase conditionally approved in Europe for desensitization of highly sensitized patients before kidney transplantation. We present 5-y outcomes and donor-specific antibody (DSA) levels for clinical trial participants from a single site who received imlifidase for desensitization before incompatible transplantation (NCT02790437).
Methods: Imlifidase was administered up to 24 h before living or deceased donor kidney transplantation.
Trans R Soc Trop Med Hyg
January 2025
Department of Microbiology and Parasitology, Federal University of Rio Grande do Norte 59078-900, Natal, Brazil.
Background: Determining esophageal and colon involvement in patients with Chagas disease occurs through invasive and uncomfortable examinations, which in most cases are not performed. The objective of this study was to assess the involvement of anti-M2-pyruvate kinase (M2-PK) autoantibodies in the development of digestive alterations and/or in the diagnosis of the digestive form of human Chagas disease.
Methods: The total IgG and isotype (IgG1, IgG2, IgG3, IgG4) production was quantified using the antigen of Trypanosoma cruzi and the human M2-PK recombinant protein via the ELISA technique.
J Immunother Cancer
January 2025
Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, USA.
Background: SL-172154 is a hexameric fusion protein adjoining the extracellular domain of SIRPα to the extracellular domain of CD40L via an inert IgG-derived Fc domain. In preclinical studies, a murine equivalent SIRPα-Fc-CD40L fusion protein provided superior antitumor immunity in comparison to CD47- and CD40-targeted antibodies. A first-in-human phase I trial of SL-172154 was conducted in patients with platinum-resistant ovarian cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!